brolucizumab-dbll (Beovu)
brolucizumab-dbll is an FDA-licensed reference biologic from Novartis Pharmaceuticals Corporation. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2022
Reference approved
Reference product
Beovu brolucizumab-dbll
Novartis Pharmaceuticals Corporation
- Approved
- May 27, 2022
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for brolucizumab-dbll, in chronological order.
Reference approval
Approval date of the reference brolucizumab-dbll product.
4 yr 1 mo ago
Frequently asked questions
Are there biosimilars approved for brolucizumab-dbll (Beovu)?
No 351(k) biosimilars or interchangeable biosimilars referencing brolucizumab-dbll are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.